key: cord-0747780-spkjn8bq authors: Konrath, Kylie M.; Liaw, Kevin; Wu, Yuanhan; Zhu, Xizhou; Walker, Susanne N.; Xu, Ziyang; Schultheis, Katherine; Chokkalingam, Neethu; Chawla, Himanshi; Du, Jianqiu; Tursi, Nicholas J.; Moore, Alan; Adolf-Bryfogle, Jared; Purwar, Mansi; Reuschel, Emma L.; Frase, Drew; Sullivan, Matthew; Fry, Benjamin; Maricic, Igor; Andrade, Viviane M.; Iffland, Christel; Crispin, Max; Broderick, Kate E.; Humeau, Laurent M.P. F.; Patel, Ami; Smith, Trevor R.F.; Pallesen, Jesper; Weiner, David B.; Kulp, Daniel W. title: Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection date: 2022-01-11 journal: Cell Rep DOI: 10.1016/j.celrep.2022.110318 sha: 07b9533e2f0c679678a44ae84a9ac499ba44d033 doc_id: 747780 cord_uid: spkjn8bq SARS-CoV-2 vaccines may target epitopes which reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally immune focused SARS-CoV-2 Spike-based vaccines. Glycans can be employed to alter antibody responses to infection and vaccines. Utilizing computational modeling and in vitro screening, we have incorporated glycans into the Receptor-Binding Domain (RBD) and assessed antigenic profiles. We demonstrate that glycan-coated RBD immunogens elicit stronger neutralizing antibodies and have engineered seven multivalent configurations. Advanced DNA delivery of engineered nanoparticle vaccines rapidly elicits potent neutralizing antibodies in guinea pigs, hamsters and multiple mouse models, including human ACE2 and human antibody repertoire transgenics. RBD nanoparticles induce high levels of cross-neutralizing antibodies against variants-of-concern with durable titers beyond six months. Single, low dose immunization protects against a lethal SARS-CoV-2 challenge. Single-dose coronavirus vaccines via DNA-launched nanoparticles provide a platform for rapid clinical translation of potent and durable coronavirus vaccines. non-nAb(s). We did not observe effects on binding to our antibody panel for glycans at 518, 519 and 520. We noticed similar antigenic patterns in glycan positions that reduce binding to some of the non-nAbs as 121 well as nAbs in RBS-E and RBS-F, suggesting there is overlap in these nAb and non-nAb epitopes. In sum, 122 our experimental screening exhaustively evaluated the effect of N-linked glycans on the expression and 123 antigenic profile of the RBD. 124 125 N-linked glycan decoration improves RBD directed immunity We utilized our single glycan data to add 126 sets of glycans to the RBD that maximally cover multiple non-neutralizing epitopes and preserve 127 accessibility to RBS targeted neutralizing epitopes. To this end, we constructed a glycan distance map 128 allowing design of three, five and eight glycan combinations which were experimental tested to determine 129 if the sets could provide optimized antigenic profiles ( Figure 3A , S1C, S1D, S1E Figure 4B ). Strikingly, rapid antibody responses were detected just 1 week after immunization with 169 RBD g5.1 24mer, RBD 48mer and RBD g5.1 120mer ( Figure 4B ). In parallel, we expressed and purified 170 nanoparticles in vitro. In contrast to wild type RBD multimers, which we could not purify and were not 171 more immunogenic than RBD monomer ( Figure Figure S6A ). We also observed live SARS-CoV-2 virus neutralization titers above the limit of 204 detection for all three nanoparticle groups with mean ID50 of 451, 1028, and 921 for RBD g5.1 120mer 205 1g, 5g and RBD g5.1 24mer 5g, respectively, compared to a mean ID50 of 29 of RBD monomer ( Figure 206 5B). The mice were infected with a high dose of SARS-CoV-2 1x10 5 PFU/mouse intranasally and 207 monitored for signs of deteriorating health. We observed that mice immunized with nanovaccines had 208 higher levels of protection from weight loss ( Figure 5C ). As expected, the naive group of animals reached 209 100% morbidity by day 6 and 1/10 animals survived in the RBD monomer group. In both RBD g5.1 120mer 210 groups had 6/10 mice survived the challenge. Strikingly, immunization with RBD g5.1 24mer provided full 211 protection from a lethal SARS-CoV-2 challenge ( Figure 5D ). All but one animal that survived had a live 212 virus neutralization titer of >100 and 12/15 of the mice that succumbed to infection did not have appreciable 213 neutralization titers ( Figure 5E ). We observed a significant correlation between live virus neutralization 214 ID50 titer and body weight loss ( Figure 5F ). Viral replication was absent in nasal turbinate which may 215 decrease viral transmissibility, and was reduced in lung tissue and brain tissue for mice immunized with 216 nanovaccines relative to RBD monomer or naïve animals ( Figure 5G ) We assessed RBD g5.1 24mer in Hartley guinea pigs (n=6) to examine intradermal vaccine delivery at 0.5, 230 5 and 10g in comparison to RBD monomer at 10g. In contrast to the RBD monomer immunized group, 231 we observed full seroconversion of RBD g5.1 24mer immunized animals at a dose of 5g ( Figure 6D ). High levels of neutralizing antibodies were obtained in the 10g dose group (ID50 of 1840) ( Figure 6E ). In In conclusion, we have developed single-dose SARS-CoV-2 nanovaccine with a platform that can afford 299 rapid pre-clinical reconfiguration to address variants of concern and for clinical translation. Human Influenza A 834 Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit 842 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but 846 Broadly Protective Viral Epitope SARS-CoV-2 neutralizing 850 antibody structures inform therapeutic strategies Two-860 component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection Potent neutralizing antibodies from COVID-19 patients define 869 multiple targets of vulnerability SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding 873 Domain Compete for ACE2 Binding. mSphere Development of an 876 epithelium-specific expression cassette with human DNA regulatory elements for 877 transgene expression in lung airways Mosaic nanoparticles elicit cross-reactive immune responses 881 to zoonotic coronaviruses in mice Mapping the immunogenic landscape of near-888 native HIV-1 envelope trimers in non-human primates A Universal Design of Betacoronavirus Vaccines against COVID-19, 892 MERS, and SARS 896 Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the 897 immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers Enhancing glycan occupancy of soluble HIV-1 904 envelope trimers to mimic the native viral spike An interactive web-based dashboard to track COVID-19 906 in real time Introduction of neutralizing immunogenicity index to 909 the rational design of MERS coronavirus subunit vaccines Data, disease and diplomacy: GISAID's innovative 911 contribution to global health DNA vaccines: prime time is now 918 Knockout rats via embryo microinjection of zinc-finger nucleases Glycosylation as a tool for rational vaccine design Self-assembling nanoparticles presenting receptor binding domain and stabilized 932 spike as next-generation COVID-19 vaccines Neutralization of SARS-CoV-2 by Destruction of the 938 Prefusion Spike A stable trimeric influenza hemagglutinin stem as a broadly 945 protective immunogen Hyperglycosylated stable core immunogens designed to present the 948 CD4 binding site are preferentially recognized by broadly neutralizing antibodies Human neutralizing antibodies 953 elicited by SARS-CoV-2 infection Immunological basis for enhanced immunity 955 of nanoparticle vaccines Influenza virus hemagglutinin stalk-based antibodies and 957 vaccines Structure-based design of native-like 962 HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding Antibody-dependent 965 enhancement and SARS-CoV-2 vaccines and therapies On the Calculation of TCID50 for Quantitation of Virus 967 Infectivity Functional assessment of cell entry and receptor 969 usage for SARS-CoV-2 and other lineage B betacoronaviruses Potent neutralizing antibodies against multiple epitopes on SARS-974 CoV-2 spike V2 loop glycosylation of the human immunodeficiency virus 976 type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 977 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 978 binding site antibodies Nanoparticle Vaccines 982 Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV Elicit Robust Protective Immune Responses 985 Nanoparticles target distinct dendritic cell populations according to their size Lethal infection of K18-hACE2 mice infected with severe 990 acute respiratory syndrome coronavirus Glycosylations in the globular head of the hemagglutinin protein 994 modulate the virulence and antigenic properties of the H1N1 influenza viruses CORTI, D. & 1014 VEESLER, D. 2020. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody 1028 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Comparison of 1032 transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection CoV-AbDab: the 1035 Epitope-focused vaccine design against influenza A and B viruses Convergent antibody responses to SARS-CoV-2 in convalescent individuals 1053 Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a 1054 small animal model CTFFIND4: Fast and accurate defocus estimation from 1056 electron micrographs A next-generation cleaved, soluble HIV-1 Env trimer A Bayesian view on cryo-EM structure determination Analysis of a SARS-CoV-2-Infected Individual Reveals 1069 Development of Potent Neutralizing Antibodies with Limited Somatic Mutation A human 1074 neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-1080 neutralizing antibodies for SARS-related viruses Immunogenicity of a 1090 DNA vaccine candidate for COVID-19 Rapid 1098 Generation of Neutralizing Antibody Responses in COVID-19 Patients A COVID-19 vaccine candidate using SpyCatcher 1110 multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces 1111 potent neutralising antibody responses Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-1114 specific human monoclonal antibody Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in 1124 Vaccinated Animals and Infected Patients Elicitation of Potent 1132 Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-1133 CoV-2 Evaluation of candidate vaccine 1139 approaches for MERS-CoV Glycan shielding of the influenza virus 1141 hemagglutinin contributes to immunopathology in mice Site-specific 1144 glycan analysis of the SARS-CoV-2 spike Exploitation of glycosylation 1146 in enveloped virus pathobiology Antibody neutralization and escape by HIV-1. 1150 Neutralizing antibody responses to SARS-CoV-2 in a 1153 COVID-19 recovered patient cohort and their implications medRxiv An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 1157 Receptor Binding Domain A noncompeting pair of human neutralizing 1161 antibodies block COVID-19 virus binding to its receptor ACE2 1163 Incorporation of a Novel CD4+ Helper Epitope Identified from Aquifex aeolicus Enhances 1164 Humoral Responses Induced by DNA and Protein Vaccinations. iScience A DNA-Launched Nanoparticle Vaccine Elicits CD8(+) T-cell Immunity to 1168 Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity Hemagglutinin-stem nanoparticles generate 1180 heterosubtypic influenza protection & 1182 DOYMAZ, M. Z. 2020. Discordance between Serum Neutralizing Antibody Titers and the 1183 Recovery from COVID-19 DNA vaccine protection 1193 against SARS-CoV-2 in rhesus macaques Recognition of the SARS-CoV-2 receptor 1195 binding domain by neutralizing antibodies 1197 A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and 1198 SARS-CoV A platform incorporating trimeric 1203 antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to 1204 elicit substantially higher neutralizing responses than spike alone 1206 Nanoparticle vaccines Structural basis for the 1214 neutralization of SARS-CoV-2 by an antibody from a convalescent patient A pneumonia outbreak 1220 associated with a new coronavirus of probable bat origin